Close menu




July 4th, 2024 | 07:05 CEST

Takeover battle, boom, and price surge: Evotec, Siemens Energy, Royal Helium in focus

  • Helium
  • renewableenergies
  • Biotech
Photo credits: pixabay.com

Is Evotec heading for a takeover battle? The share price crash has likely attracted private equity. Now, the biotech company is said to have hired an investment bank for defence plans. An order from the US Department of Defense comes at the right time. Helium is also likely to gain importance in the US. The noble gas is indispensable for quantum computers, rockets, and other high-tech applications. In Canada, Royal Helium is currently making the transition from explorer to producer. The share is ripe for a price surge. Siemens Energy's share price currently only knows the way up. And according to analysts, a further 50% is possible.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: ROYAL HELIUM LTD. | CA78029U2056 , EVOTEC SE INH O.N. | DE0005664809 , SIEMENS ENERGY AG NA O.N. | DE000ENER6Y0

Table of contents:


    Royal Helium: Breaking from the bottom formation?

    The importance of helium is massively underestimated by the general public. On the one hand, it is necessary for technical processes that use superconducting magnets, such as in magnetic resonance imaging. The noble gas is practically irreplaceable as a coolant in the field of high technology, including particle accelerators and quantum computers. There is also no alternative to helium in the semiconductor industry, in rockets and fibre optic cables.

    Royal Helium is currently taking the exciting step for investors from explorer to helium producer and aims to become a globally renowned supplier in the coming years. The Company has secured more than 400,000 hectares of promising helium concessions and leases in Canada. In the Canadian province of Saskatchewan, the Val Marie project is being developed together with Sparrow Hawk Developments. The cooperation partner is providing an impressive CAD 25 million for the project.

    The Steveville project is already in production. The purification plant can process 15 million cubic feet of raw gas per day and is supplied from two helium wells drilled by Royal. Steveville is designed to last 25 years.

    Royal CEO Andrew Davidson: "*We are pleased that the helium purification plant at Steveville is running at a steady production rate and that the entire team is moving the plant into the final stages of capacity expansion under the world-class supervision of Progress Through Technology. *The plant is designed to be fully automated and self-powered so that once it reaches a steady state, the operation can quickly become cash flow positive with very low operating costs."** The plant will benefit from carbon credits and provide Royal Helium with additional cash flow.

    Royal shares are also traded on Tradegate in Germany and have been bottoming between 5 and 6 euro cents since April. With the positive operating newsflow and the demand for helium, there is significant upside potential. After all, the share was already trading at 50 euro cents in 2021 and was not nearly as advanced operationally as it is today.

    Evotec supports US army and fights for independence

    Will Evotec soon be facing a takeover battle? According to a report in the "FAZ" newspaper, the biotech company is preparing for such a scenario. Bank of America is said to have been mandated to draw up concepts for fending off takeover attempts. Private equity companies are apparently taking a closer look at Evotec. The takeover rumors have given the share a boost in recent days, and the attempt to exceed the EUR 10 mark is underway.

    Operationally, an order from the US Department of Defense was recently reported. Evotec's subsidiary Just is to develop monoclonal antibodies for the rapid response capability of medical countermeasures. The contract has a volume of up to USD 39 million. The production solution optimized by Just will be seamlessly integrated into the US government's rapid emergency response system. Just manager Dr. Linda Zuckerman: "We are proud to have been selected to provide our expertise and technologies to support this important program. We look forward to advancing our end-to-end biologics development platform and partnering with the DOD to bring mAbs to the clinic with next-generation development in a rapid, high-quality and cost-effective manner."

    Siemens Energy facing a golden future?

    While Evotec has to prepare for a takeover after the share price decline, Siemens Energy is bursting with strength. At the end of 2023, the Company was still surrounded by the spectre of insolvency. The problems at subsidiary Gamesa seemed to be a bottomless pit that dragged the entire Group down. But this has long been forgotten - or at least overlooked. The Siemens Energy share is one of the top performers of the current year, and the strong development in the grid business overshadows potential problem areas.

    In an interview with the "Süddeutsche Zeitung", Tim Holt, the Managing Board member responsible for the Grid Technologies division, said: "*In the next 15 years, we will see investments in the grid worldwide that are as large as those of the last 150 years. *We want to participate in this boom and are therefore investing a total of EUR 1.2 billion by 2030 and creating around 10,000 jobs." The jobs are to be created in Germany, the UK, Austria, Croatia and, to a lesser extent, Romania. In the first half of 2024 alone, the grid division recorded an order intake of over EUR 12 billion. Previously, the order volume had already more than doubled from EUR 7 billion to EUR 15 billion in just three years.

    For Goldman Sachs, Siemens Energy's investment plans indicate that the division's medium-term targets are too conservative and offer scope for increases. The "Buy" recommendation was therefore confirmed. The price target of EUR 32.70 is a good 50% above the current level.


    The Siemens Energy share has already had a fantastic run this year, and a consolidation would be healthy. Operationally, however, everything seems to be going well, but Gamesa remains a risk. There are also risks with Evotec. However, many negative factors are likely priced into the current share price. By contrast, Royal Helium's operating progress is not yet reflected in the share price. If the share breaks out, it could go up very quickly.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Nico Popp on March 31st, 2026 | 08:20 CEST

    Dividends as Portfolio Anchors: Familiar Names Sanofi and BB Biotech – Hidden Gem RE Royalties

    • royalties
    • dividends
    • Biotech
    • Pharma
    • Sustainability
    • renewableenergy

    In a market environment marked by structural upheaval, portfolio stability is increasingly coming into focus. Analysts at JPMorgan emphasize that preserving accumulated gains requires a renewed focus on resilience and diversification. Research by S&P Global also shows that dividends have contributed over 50% to the total return of global equities over the past 25 years. Choosing the right stocks is crucial to securing steady cash flows even during volatile market phases. Pharmaceutical giant Sanofi, investment firm BB Biotech, and the virtually unknown Canadian company RE Royalties offer fundamentally different but extremely promising approaches for investors.

    Read

    Commented by Nico Popp on March 30th, 2026 | 08:30 CEST

    A Paradigm Shift in Oncology: Core Stocks Roche & Galderma and the High-Leverage Opportunity in Vidac Pharma

    • Biotechnology
    • Biotech
    • Pharma
    • Innovations
    • Cancer

    Medical advances affect us all. Oncology is also undergoing a transformation. As conventional immunotherapies for skin cancer increasingly reach their limits, clinical research is shifting its focus to correcting defective tumor metabolism. The Warburg effect, where cancer cells shift energy production to aerobic glycolysis to fuel uncontrolled growth, offers a promising entry point. This dynamic development landscape is exacerbated by an impending patent cliff, which, according to calculations by the consulting firm PwC, threatens industry revenues of USD 104 billion by 2028, as many patents for active ingredients are expiring. Currently, market researchers at Fortune Business Insights estimate the volume of the global oncology market for 2026 at USD 286.36 billion. While pharmaceutical giant Roche secures its market leadership and the Galderma Group dominates standard dermatological care, biotechnology company Vidac Pharma is targeting the metabolic vulnerability of cancer cells with a completely novel mechanism of action, aiming to effectively shut down the cancer.

    Read

    Commented by Fabian Lorenz on March 26th, 2026 | 06:55 CET

    Over 50% Upside Potential? BioNTech, TUI, and Bayer Partner MustGrow

    • Agriculture
    • agritech
    • fertilizer
    • mustard
    • Biotech

    Looking for an under-the-radar opportunity with significant upside potential? MustGrow may fit the profile. With a market capitalization of under CAD 40 million, its biological and regenerative crop protection solutions have already attracted the interest of Bayer. The Leverkusen-based company has licensed the mustard seed-based technology for Europe, Africa, and the Middle East and is investing a double-digit million amount. A full takeover is also not out of the question. Meanwhile, takeover speculation surrounding BioNTech has eased following the founders' surprise departure, and attention is slowly shifting back to the research pipeline. Analysts have confirmed their "Buy" recommendation. The same applies to TUI. The war in Iran is causing uncertainty among investors, while the company is simultaneously reporting an increase in flight capacity for the spring and summer seasons.

    Read